CClinicalTrials.gg
Sign In
CompletedNCT05027191Updated Aug 30, 2021

Effect of Desflurane Versus Sevoflurane With Recent Bio-markers on Renal and Hepatic Functions

An observational study in Postoperative Complications, sponsored by Theodor Bilharz Research Institute. Completed at 1 site in Egypt. Open to participants aged 25 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-08-30.

Sponsored by Theodor Bilharz Research Institute · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
70
Ages
25 Years to 55 Years
Sex
All
01

Study summary

Studying the effects of both inhalational anesthetics desflurane and sevoflurane on hepatic integrity and renal function, guided by recent blood and urine biomarkers in patients undergoing laparoscopic cholecystectomy surgery.

02

Conditions studied

  • Postoperative Complications
03

In context

Postoperative Complications

1,233 studies on the registry are indexed under Postoperative Complications; 292 are open to participants now.

This study's enrollment of 70 is below the median of 254 across 519 observational studies indexed under Postoperative Complications.

Browse Postoperative Complications studies →

Lead sponsor

Theodor Bilharz Research Institute is the lead sponsor of 36 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

After informed written consents have been taken, this study will be conducted on 70 patients scheduled for laparoscopic cholecystectomy. The patients will be randomly allocated into two groups (a desflurane (D) group and a sevoflurane (S) group) using a sealed envelope technique for each group.

Inclusion criteria

  1. American Society of Anesthesiologists (ASA) Class: I\&II.
  2. Elective laparoscopic cholecystectomy.
  3. Age: 25-55 years.
  4. Gender: Both male and female.
  5. Body Mass Index (BMI): 18.5-24.9 km2-(Normal weight).

Exclusion criteria

Exclusion Criteria:

  1. Extremes of age.
  2. Abnormal hepatic function by alanine aminotransferase (ALT) and aspartate aminotransferase (AST) values outside the normal range.
  3. Abnormal renal function by blood urea nitrogen (BUN) and creatinine above the normal ranges.
  4. Hypertension, unstable angina pectoris or myocardial infarction within the last six months.
  5. Pregnancy and lactation.
  6. Bronchial asthma.
  7. Drug allergies.
  8. Alcohol or drug addiction.
  9. General anesthesia within the last three months.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
70 participants (actual)
Patient registry
No

Groups and cohorts

  • Sevoflurane

    This group will receive sevoflurane as the maintenance inhalational anesthetic.

    Diagnostic Test: Neutrophil Gelatinase-Associated Lipocalin (NGAL) · Drug: Sevoflurane

  • Desflurane

    This group will receive desflurane as the maintenance inhalational anesthetic.

    Diagnostic Test: Neutrophil Gelatinase-Associated Lipocalin (NGAL) · Drug: Desflurane

Interventions

  • Diagnostic testNeutrophil Gelatinase-Associated Lipocalin (NGAL)

    The evaluation of inhalational anesthetics (desflurane and sevoflurane) on NGAL levels in laparoscopic cholecystectomy patients.

  • DrugDesflurane

    Desflurane

  • DrugSevoflurane

    Sevoflurane

06

What researchers measure

Primary outcomes

  1. Change in serum Neutrophil gelatinase-associated lipocalin (NGAL)

    Renal Biomarker

    Time frame: a change from baseline NGAL serum level at 6 hours

Secondary outcomes

  1. Change in serum Arginase

    Hepatic biomarker

    Time frame: Baseline, first hour, six hours, after 24 hours

  2. Change in serum Cystatin-c

    Hepatic biomarker

    Time frame: Baseline, first hour, six hours, after 24 hours

  3. Change in urine Netrin-1

    Renal biomarker

    Time frame: Baseline, first hour, six hours, after 24 hours

  4. Change in urine Kidney Injury Molecule

    Renal biomarker

    Time frame: Baseline, first hour, six hours, after 24 hours

  5. Change in urine Interleukin-18

    cytokines

    Time frame: Baseline, first hour, six hours, after 24 hours

  6. Change in urine Alpha-Glutathione S-Transferase

    Liver biomarker

    Time frame: Baseline, first hour, six hours, after 24 hours

07

Study locations

1 site
  • Theodor Bilharz Research Institute
    Cairo, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05027191
Lead sponsor
Theodor Bilharz Research Institute
Collaborators
Cairo University
Responsible party
khalda Galal Moustafa (Principal Investigator, Theodor Bilharz Research Institute) — Principal investigator
First posted
Aug 30, 2021
Start date
Feb 15, 2018
Primary completion
Nov 20, 2019
Completion
Dec 1, 2019
Last update
Aug 30, 2021

Study contacts

Khalda G Radwan, MD
principal investigator · Theodor Bilharz Rsearch Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Postoperative Complications→

Other studies from this sponsor

Theodor Bilharz Research Institute

Start the discussion